Clinical trial
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum…
NCT00220194 · San Bernardino Urological Associates Medical Group Inc, Other · Completed
Key facts
| NCT number | NCT00220194 |
|---|---|
| Title | A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer |
| Official title | A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer |
| Lead sponsor | San Bernardino Urological Associates Medical Group Inc, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cancer of Prostate |
| Intervention type | Drug |
| Interventions | leuprolide acetate |
| Enrollment | 100 |
| Start date | Apr 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Oct 14, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: